Latest News & Features
Biotechnology
Biotech claims action was necessary due to unfavourable rulings after being targeted by a rival | Accuses gene technology firm of attempting to shrink the competitive landscape for different spatial biology platforms. 6 February 2024
Big Pharma
Oncology specialist seeks to block another bendamustine generic following trio of lawsuits in January | Firm filed complaint for patent infringement against Dr Reddy’s. 6 February 2024
Americas
Firm adds to its New York office with the appointment of ANDA expert as a partner in litigation group | Represented clients such as Gilead, Sanofi-Aventis, and Bristol-Myers Squibb in high-stakes cases. 1 February 2024
Big Pharma
PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation. 1 February 2024
Americas
Pharma giants raise concerns about Moderna’s COVID-19 vaccine patents | Company's statements to the FDA and PTAB contain "inconsistencies" | Appeals Board urged to scrutinise assertions. 1 February 2024
Biotechnology
MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body. 30 January 2024
Medtech
Biotech firm CareDx found to have infringed one of two patents-in-suit through sale of AlloSure and AlloSeq | Damages award consists of $83.6m in lost profits and $12.6m in royalties. 30 January 2024
Big Pharma
Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival. 25 January 2024
Biotechnology
Despite the clamour for guidance, applicants, attorneys, and lawyers may be in for a frustrating wait before the UK updates AI protections, says Rebecca Lawrence of DLA Piper. 25 January 2024
Big Pharma
Sun Pharma’s Sezaby, used to treat infant seizures, infringes two patents says Nivagen | US firm accuses Indian rival of attempting to block patent from issuing. 25 January 2024